THE INTEGRIN ACTIVATION INTERFACE

摘要

The specific molecular basis of the interaction between talin and integrin ß₃ has been defined. This specific interaction provides a new therapeutic target; agents that can disrupt this specific interaction should be useful therapeutic agents for a number of significant diseases and conditions including inflammation, heart disease, including myocardial infarction, and tumor metastasis. The present invention includes a chimeric peptide that has high affinity for talin, muteins of talin and integrin ß₃ as well as screening methods for agents that can disrupt the interaction between talin and integrin ß₃.